Hyundai Mobis developed a brainwave detection device dubbed M. Brain to alert motor vehicle operators against drowsy driving or sudden health issues.
The M.Brain analyzes brainwaves to determine the driver’s health conditions and attention levels in real-time, using earpiece sensors.
When the driver loses attention, a smartphone app, light-emitting diodes around the driver, vibrating seats, and headrest speakers send warning signals.
Hyundai Mobis claims the M.Brain is the world's first measuring device for brainwaves, one of the most difficult biosignals to analyze.
The company said it adopted some of the latest technologies, such as machine learning to interpret the brainwave signals, over the last three years.
Hyundai Mobis said it will partner with Gyeonggi Province to test the brainwave detectors in public buses running in the province and expand application in the future.
The brainwave detection technology could also be applied to monitor the conditions of both drivers and passengers. Thus, the vehicle could automatically adjust to satisfy individual needs, such as directing the vehicle to an emergency room when the device detects a passenger's health issues.


Oil Prices Surge Amid U.S.-Iran Tensions and Strait of Hormuz Disruptions
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
U.S. Stock Futures Fall as Iran Tensions Escalate and Oil Prices Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
China vs. NASA: The New Moon Race and What's at Stake by 2030
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Oil Prices Dip as Middle East Peace Hopes Grow Amid Iran-U.S. Talks
Asian Stocks Rise as Tech Gains Offset US-Iran Tensions, Oil Prices Add Pressure
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Iran Closes Strait of Hormuz Again After Brief Reopening, Rattling Global Energy Markets
Morgan Stanley Warns Against Overestimating EV Demand Boost from Rising Oil Prices
Japan Inflation Expectations Rise as BOJ Rate Hike Timing Faces Uncertainty
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



